UPDATE: Canaccord Genuity Starts Delcath Systems (DCTH) at Buy

March 9, 2021 5:42 AM EST
Get Alerts DCTH Hot Sheet
Price: $10.23 -1.63%

Rating Summary:
    4 Buy, 2 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 10 | Down: 12 | New: 30
Trade Now! 
Join SI Premium – FREE
(Updated - March 9, 2021 7:52 AM EST)

Canaccord Genuity analyst Arlinda Lee initiates coverage on Delcath Systems (NASDAQ: DCTH) with a Buy rating and a price target of $24.00.

The analyst commented, "We initiate coverage of Delcath Systems with a BUY rating and $24 price target. Delcath’s Hepzato, a combination drug and device liver-directed therapy, has established efficacy, but has not achieved US regulatory approval due to its safety profile in earlier iterations. With multiple measures to mitigate safety issues into the ongoing Ph3 FOCUS trial in ocular melanoma patients with liver metastases, and with multiple Orphan designations, we are cautiously optimistic Hepzato can show a positive efficacy-safety profile."

For an analyst ratings summary and ratings history on Delcath Systems click here. For more ratings news on Delcath Systems click here.

Shares of Delcath Systems closed at $17.65 yesterday.


You May Also Be Interested In





Related Categories

Analyst Comments, New Coverage

Related Entities

Canaccord Genuity